Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00516698 · ClinicalTrials.gov registry record

Changes in Breast Density and Blood Hormone Levels in Postmenopausal Women Receiving Anastrozole or Exemestane for Breast Cancer

A clinical trial of Breast Cancer, sponsored by Alliance for Clinical Trials in Oncology.

Completed
Registry status
140
Enrollment target
20
Study locations

NCT00516698: Completed study of Breast Cancer, sponsored by Alliance for Clinical Trials in Oncology.

NCT00516698 is a study of Breast Cancer that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 140 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00516698, a study of Breast Cancer, has completed, sponsored by Alliance for Clinical Trials in Oncology.

COMPLETED
Registry status
140 participants
Enrollment target
20
Study locations

Study Summary

RATIONALE: Studying changes in breast density and blood hormone levels in women receiving anastrozole or exemestane for breast cancer may help doctors learn more about the long-term effects of treatment and may help the study of breast cancer in the future. PURPOSE: This clinical trial is studying changes in breast density and blood hormone levels in postmenopausal women receiving anastrozole or exemestane for breast cancer.

Conditions Studied

Interventions

  • OTHER laboratory biomarker analysis
  • GENETIC polymorphism analysis
  • OTHER high performance liquid chromatography
  • PROCEDURE radiomammography

Study Locations (20)

Illinois

  • Rush-Copley Cancer Care Center - Aurora
  • St. Joseph Medical Center - Bloomington
  • Graham Hospital - Canton
  • Memorial Hospital - Carthage
  • St. Anthony's Memorial Hospital - Effingham
  • Eureka Community Hospital - Eureka
  • Galesburg Clinic, PC - Galesburg
  • Galesburg Cottage Hospital - Galesburg
  • Mason District Hospital - Havana
  • Hopedale Medical Complex - Hopedale
  • Joliet Oncology-Hematology Associates, Limited - West - Joliet
  • McDonough District Hospital - Macomb
  • Trinity Cancer Center at Trinity Medical Center - 7th Street Campus - Moline
  • - Moline
  • BroMenn Regional Medical Center - Normal
  • Community Cancer Center - Normal
  • Community Hospital of Ottawa - Ottawa
  • Oncology Hematology Associates of Central Illinois, PC - Ottawa - Ottawa
  • Cancer Treatment Center at Pekin Hospital - Pekin

Georgia

  • MBCCOP - Medical College of Georgia Cancer Center - Augusta

Trial Details

FieldValue
Enrollment Target 140 participants
Start Date 2007-09
Est. Completion 2009-12

What the finished NCT00516698 record still lists

NCT00516698 is an observational study that tracks outcomes without assigning an intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower).

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which laboratory biomarker analysis is the first listed.

NCT00516698 names 20 study sites across 2 states, led by Illinois, Georgia.

Frequently Asked Questions

What is clinical trial NCT00516698 about?

NCT00516698 is a clinical study titled "Changes in Breast Density and Blood Hormone Levels in Postmenopausal Women Receiving Anastrozole or Exemestane for Breast Cancer". RATIONALE: Studying changes in breast density and blood hormone levels in women receiving anastrozole or exemestane for breast cancer may help doctors learn more about the long-term effects of treatment and may help the study of breast cancer in the future. PURPOSE: This clinical trial is studying ...

What is the current status of trial NCT00516698?

This trial is currently completed. The enrollment target is 140 participants. The study started on 2007-09. Estimated completion is 2009-12.

What conditions does trial NCT00516698 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT00516698?

The interventions under investigation include: laboratory biomarker analysis (OTHER), polymorphism analysis (GENETIC), high performance liquid chromatography (OTHER), radiomammography (PROCEDURE).

Who is sponsoring clinical trial NCT00516698?

This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00516698 being conducted?

This trial has 20 study locations across Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00516698's enrollment target sits among peer trials

140 464th of 1224 higher than 757 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01419561 · 140 participants · Phase 2

    Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)

  • NCT01624805 · 140 participants · Phase 2

    Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome

  • NCT02369770 · 140 participants · NA

    Sensory-Motor Rehabilitation Post Stroke

  • NCT02455193 · 140 participants · NA

    Neuronal Effects of Exercise in Schizophrenia

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00516698, the US trial registry maintained by the National Library of Medicine. NCT00516698 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.